Original Publication Date: 24 March, 2014
Publication / Source: Future Oncology
Authors: Giuseppina Campisi, Stefano Fedele, Vittorio Fusco, Giuseppe Pizzo, Olga Di Fede & Alberto Bedogni
Osteonecrosis of the jaws (ONJ) is an adverse side event of bisphosphonates and denosumab, antiresorptive agents that effectively reduce the incidence of skeletal-related events in patients with metastatic bone cancer and multiple myeloma. Available data suggest that 0–27.5% of individuals exposed to antiresorptive agents can develop ONJ. There is increasing evidence that avoidance of surgical trauma and infection to the jawbones can minimize the risk of ONJ, but there are still a significant number of individuals who develop ONJ in the absence of these risk factors.